PATTERN OF PSA CHANGE DURING SERIAL SCREENING IN THE PLCO CANCER SCREENING TRIAL AFFECTS PROSTATE CANCER RISK
Robert L. Grubb, Gerald L. Andriole(Institut thématique Génétique, génomique et bioinformatique), Timothy R. Church(University of Minnesota), Paul F. Pinsky(National Cancer Institute), Amanda Black(St. Elizabeth's Hospital), Jerome Mabie(Information Management Services), Lawrence R. Ragard(Westat (United States)), E. David Crawford(University of Colorado Denver), Christine D. Berg(Prevention Group), Thomas Hickey(Information Management Services), Douglas J. Reding(Ascension), Grant Izmirlian(National Institutes of Health), Thomas Riley(National Cancer Institute), Philip C. Prorok(National Cancer Institute)
Cited by 0
Related Papers
Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood
|New England Journal of Medicine|1993|3.3k
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k
Probability of Cancer in Pulmonary Nodules Detected on First Screening CT
|New England Journal of Medicine|2013|1.4k
The Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal Cancer
|New England Journal of Medicine|2000|1.4k